COMP <GO>
SRTA vs STLN // EV/EBITDA & P/E VALUATION
Strata Critical Medical Inc. (Class A) (NASDAQ) VS. Starling Oncology Inc. (NASDAQ) • 15-METRIC TALLY: SRTA 4
— STLN 5
■ METRIC PARITY
LAST: $4.75 (-0.21%) • MKT CAP: $420.2M
valuation
—
LAST: $6.65 (+0.15%) • MKT CAP: $677.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRTA VS. STLN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRTA | STLN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 20.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -7.10% | -35.00% | +27.90 | SRTA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -13.92% | -4.10% | -9.82 | STLN | /fcf-yield <GO> |
| Operating Margin | -11.30% | -7.20% | -4.10 | STLN | /operating-margins <GO> |
| Net Profit Margin | 21.00% | 68.00% | -47.00 | STLN | /net-margins <GO> |
| Revenue Growth (YoY) | 34.30% | 27.80% | +6.50 | SRTA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.58 | 2.58 | +3.00 | SRTA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | SRTA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.4 | 49.5 | -13.05 | STLN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.6x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $420.2M | $677.7M | -$257.5M | STLN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRTA REV | STLN REV | SRTA GROSS % | STLN GROSS % | SRTA FCF | STLN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $197.1M | $502.7M | 20.9% | — | -$58.5M | -$27.8M |
| FY 2024 | $146.8M | $393.4M | 20.2% | — | -$33.4M | -$30.3M |
| FY 2023 | $225.2M | $324.2M | — | — | -$32.3M | -$36.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRTA // BETA —
STLN // BETA —